Home » Stocks » IRWD

Ironwood Pharmaceuticals, Inc. (IRWD)

Stock Price: $10.99 USD 0.02 (0.14%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $10.92 -0.07 (-0.64%) May 11, 7:00 AM
Market Cap 1.81B
Revenue (ttm) 398.43M
Net Income (ttm) 142.76M
Shares Out 160.97M
EPS (ttm) 0.90
PE Ratio 12.24
Forward PE 9.88
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $10.99
Previous Close $10.98
Change ($) 0.02
Change (%) 0.14%
Day's Open 10.93
Day's Range 10.79 - 11.21
Day's Volume 1,631,851
52-Week Range 8.63 - 12.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Ironwood Pharmaceuticals (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

1 day ago - Zacks Investment Research

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations.

3 days ago - Zacks Investment Research

Ironwood (IRWD) delivered earnings and revenue surprises of 9.09% and 3.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 500.00% over the past year to $0.24, which beat t...

5 days ago - Benzinga

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

5 days ago - Business Wire

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals Reports First Quarter 2021 Results

5 days ago - Business Wire

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursd...

2 weeks ago - Business Wire

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. A media mogul was among the insiders making purchases this week.

Other stocks mentioned: MSFT, NWS, NWSA, SNOW, WMT, ADM, ADT ...
1 month ago - Benzinga

There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.

Other stocks mentioned: DHR, DTE, NLS, PRMW, SNSE, TREE
2 months ago - InvestorPlace

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. A pair of chief executives and an executive board chair were among the insiders making purc...

Other stocks mentioned: EDIT, XOM, CLI, DISCA, EPD, PRMW, TDY ...
2 months ago - Benzinga

Their recent struggles may soon give way to rising market interest and more lucrative returns.

Other stocks mentioned: CHRS, SUPN
2 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, announced that management will be presenting at the following investor conferences: SVB Leerink G...

2 months ago - Business Wire

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.

2 months ago - Zacks Investment Research

Ironwood (IRWD) delivered earnings and revenue surprises of 33.33% and 9.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 20.00% over the past year to $0.36, which beat ...

2 months ago - Benzinga

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2020 results and recent business per...

2 months ago - Business Wire

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Ironwood Pharmaceuticals Inc's (NASDAQ: IRWD) chief executive officer, Mark Mallon, will step down, effective March 12, “to pursue another leadership opportunity,” less than two years after he took the ...

3 months ago - Benzinga

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Mark Mallon plans to step down as chief executive officer and a member of th...

3 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full year 2020 investor update conference call and webcast at 8:30 a.m. Eastern...

3 months ago - Business Wire

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) has the dubious distinction of owning one of the 10 biggest drug trial flops of 2020, according to FierceBiotech. The Boston-based company's once-promising tr...

3 months ago - GuruFocus

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, will provide a corporate overview during a presentation and Q&A session at the 39th Annual J.P. M...

4 months ago - Business Wire

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as ...

5 months ago - Business Wire

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

5 months ago - Zacks Investment Research

Earnings yield can be more illuminating than the traditional P/E ratio as the former facilitates comparison of stocks with fixed-income securities.

Other stocks mentioned: ALLY, MCFT, ODP, REZI
5 months ago - Zacks Investment Research

Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in a virtual fireside chat at the 29th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2020 ...

6 months ago - Business Wire

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.

6 months ago - Zacks Investment Research

Ironwood (IRWD) delivered earnings and revenue surprises of 64.29% and 10.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its third quarter 2020 results and recent business performance. “Iron...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Alexander Denner, Ph.D., to its Board of Directors, effective November 9, 2020. Dr. Denner is th...

6 months ago - Business Wire

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2020 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursd...

6 months ago - Business Wire

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.

7 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that data from IW-3718-302, one of Ironwood’s two identical Phase III trials eval...

7 months ago - Business Wire

A catalyst is expected for Ironwood, in that it expects an IDMC decision for its phase 3 study IW-3718-302 using IW-3718 to treat patients with refractory GERD Q4 2020.

7 months ago - Seeking Alpha

These stocks hold tremendous potential despite a low price.

Other stocks mentioned: NOK, ZNGA
7 months ago - The Motley Fool

The novel coronavirus is weighing on the market, but these four biotech stocks can survive. Here's what you need to know to profit now.

Other stocks mentioned: IBB, XBI, XLV
7 months ago - InvestorPlace

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: 2020 Wells Fargo Virtual Healthcare C...

8 months ago - Business Wire

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

8 months ago - Zacks Investment Research

Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Peter Ingram on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.

9 months ago - Zacks Investment Research

Ironwood (IRWD) delivered earnings and revenue surprises of 100.00% and 6.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its second quarter 2020 results and recent business performance, as w...

9 months ago - Business Wire

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 3, 2010
CEO
Mark Mallon
Employees
232
Stock Exchange
NASDAQ
Ticker Symbol
IRWD
Full Company Profile

Financial Performance

In 2020, IRWD's revenue was $389.52 million, a decrease of -9.08% compared to the previous year's $428.41 million. Earnings were $106.18 million, an increase of 393.73%.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for IRWD stock is "Hold." The 12-month stock price forecast is 12.33, which is an increase of 12.19% from the latest price.

Price Target
$12.33
(12.19% upside)
Analyst Consensus: Hold